Top Tweets for #ejpc
New in #EJPC:
✅An unhealthy CVD risk profile in adolescence leads to structural vascular and cardiac changes in young adults, predisposing them to future CVD
📕 Read more: https://t.co/0Z3vSkutK8
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
👍 Great to see this work from the Population Science & Public Health Section of the European Association of Preventive Cardiology - EAPC now published in #EJPC.
#Collaboration #TeamWork #Exposome #CVD #Prevention @escardio @ESCardioNews
Link to paper:
https://t.co/BjletyPpMu
1/n
Our paper @EAPCPresident #EJPC on Cardiovascular health being shaped by where we live.
Walkable neighbourhoods, green spaces, clean air, healthy food access, and social connection can reduce CVD
#CardiovascularHealth #PublicHealth #Prevention
https://t.co/HJcUxWlKIJ
New in #EJPC:
✅Childhood and adolescent HDL-C are prospectively and inversely associated with adult ASCVD, suggesting that low HDLC could be a risk marker of adult ASCVD
📕 Read more: https://t.co/ncp1ISwy3L
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
Nice editorial about our upcoming publication in #EJPC @ESC_Journals A more refined estimates on longitudinal changes of Cardiorespiratory Fitness and their association with cardiovascular events and mortality. https://t.co/8iuIQ7ozKo
New in #EJPC:
✅In children with heterozygous familial hypercholesterolaemia, evolocumab plus statin treatment up to 104 weeks led to regression in carotid arterial wall thickening
📕 Read more: https://t.co/LMmi5s0GXf
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
New in #EJPC: In endurance athletes, neither atrial fibrillation nor left atrial dilation was associated with higher exercise blood pressure responses.
📕 Read more: https://t.co/zTJnzUuQTj
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
New in #EJPC: This study assessed stopping antihypertensive therapy (AHT) in pts without self-reported CV risk factors (other than hypertension) or target organ damage, on monotherapy or low-dose dual AHT.
➡️ About one-third of individuals on monotherapy or low-dose dual AHT maintained controlled BP after one year 📕 Read more: https://t.co/JTsrFeOxhn
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
New in #EJPC:
✅In patients with arterial hypertension, blood pressure reduction by renal denervation increased retinal capillary density both 6 and 12 months after the procedure.
📕 Read more: https://t.co/02QWmq8ALx
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
New in #EJPC: ✅ Single-pill combination use results in greater likelihood of achieving target blood pressure control and more rapid, sustained blood pressure reduction without an increase in serious adverse events. 📕 Read more: https://t.co/jGCPVgKjIf
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
New in #EJPC:
✅ Visit-to-visit blood pressure variability (VVV BPV) is capable of predicting CVD development in 6 year. Furthermore, electronic health record-based BPV assessment is reliable for CVD risk evaluation.
📕 Read more: https://t.co/gk05WGAN7V
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
The timing of LDL-C lowering matters. New in #EJPC : In FOURIER-OLE, earlier initiation of evolocumab was associated with a 24% ⬇️risk of complex coronary revascularization over 8 years, including fewer CABG and complex PCI procedures.
“Start intensive lipid-lowering therapy early and sustain it long term”.
https://t.co/uuwoic4zjt
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
Serving as #EJPC Associate Editor has been an immense privilege since Day 1️⃣ & seeing it reach IF of 🔟 fills me with so much joy, but even more gratitude to Prof. @AboyansV @EJPCEiC for his amazing leadership‼️ 🥰
Congrats to the entire @escardio journals’ family, too. 🥳
https://t.co/i7KQl5a9nH
Proud to share: the new impact factor of #EJPC has made a substantial leap and is now at 🔟!
Kudos 👏👏👏 to all those authors who have trusted on the scientific value of this Journal and submitted their excellent papers.
Such great news @escardio #EJPC @ESC_Journals 🎉
Congratulations @EJPCEiC 👏👏
Delighted to be part of your Associated Editor team 🙏
Proud to share: the new impact factor of #EJPC has made a substantial leap and is now at 🔟!
Kudos 👏👏👏 to all those authors who have trusted on the scientific value of this Journal and submitted their excellent papers.
Proud to share: the new impact factor of #EJPC has made a substantial leap and is now at 🔟!
Kudos 👏👏👏 to all those authors who have trusted on the scientific value of this Journal and submitted their excellent papers.
New in #EJPC: Disability is associated with higher cardiovascular risk even in young adulthood.
In adults aged 20–39 years, long-standing disability was linked to a 34% higher risk of CVD, independent of conventional risk factors. Risk was highest in brain lesion-related disability and increased with disability severity and duration.
A call for earlier and more inclusive prevention.
♿🫀https://t.co/wwp7tr32VV
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
Our new paper is out in the European Journal of Preventive Cardiology #EJPC looking at body composition changes in patients taking GLP-1 receptor agonists while going through our Pritikin intensive cardiac rehabilitation program at @UCSDCardiology
https://t.co/kNSedHYvAo
Congratulations to my mentees who led this study: UC San Diego medical students Ian Jennings and Kristine Ly, UCSD undergraduate Mariam Marooki, and research coordinators Gavin McLLaren and @marissadzotsi . Not all weight loss is equal and quality of weight loss matters. When patients lose weight on GLP-1 RAs, the muscle they keep matters just as much as the fat they lose.
Across 468 patients, those on GLP-1 RAs improved their fitness and lost fat while holding their skeletal muscle mass steady. In a structured cardiac rehab setting built around supervised resistance training, aerobic exercise, we did not see the muscle loss that has been a concern with this class of medications.
Just as important, everyone in cardiac rehab improved their fitness by roughly 3 METs, whether or not they were on a GLP-1. That is a meaningful number. Each 1-MET improvement is associated with a 10 to 25% reduction in mortality, so a gain of this size translates into a substantial improvement in cardiovascular outcomes. It is a powerful reminder of what structured cardiac rehab delivers.
The takeaway for preventive cardiology: GLP-1 therapy works best as part of a comprehensive program. Combined with structured exercise and nutrition, patients gain multiple cardiometabolic benefits and preserve the muscle that keeps them strong and functional. We need to utilize cardiac rehab more! @MWilkinsonMD @hsbhatia @dranulala @purviparwani @DrMarthaGulati @VietHeartPA @EJPCEiC @SamiaMoraMD @EugeniaGianos @JamalRanaMD @Bweber04 @MonSangh @ditchhaporia @khurramn1 @MichaelJBlaha @Jcontreras75 @emilyswlau @EmilyManoogian @SatchinPanda
New in #EJPC⚽ As excitement builds for the upcoming FIFA World Cup, the randomized #MY3F study reminds us that football is more than a game.
In patients with CAD or prior MI, once-weekly football training improved fitness, blood pressure, weight, and depressive symptoms—supporting its role in secondary prevention. ❤️ https://t.co/B0AF1EDEJB
#CardiacRehabilitation #Prevention #WorldCup
@EJPCEiC @AboyansV @SilCastelletti @PTBuketAkinci @PeroneFrancesco @SMosteoru @TimKambic
Last Seen Hashtags on Sotwe
momson filter:videos
Seen from United States
รับงานอำนาจเจริญ
Seen from Thailand
bandeàmacaronricaine
Seen from United States
momson()**
Seen from United Kingdom
fromnagasakitotheworld
Seen from United States
Nolimits nolimits
Seen from Canada
teeNager
Seen from Pakistan
fantasySupernaturalsUnderworld
Seen from United States
monkeyappwinsFull
Seen from Turkey
ديوث_اخته
Seen from Germany
Most Popular Users
Elon Musk 
@elonmusk
241.5M followers
Barack Obama
@barackobama
119.1M followers
Cristiano Ronaldo
@cristiano
113.6M followers
Donald J. Trump
@realdonaldtrump
111.8M followers
Narendra Modi
@narendramodi
107.2M followers
Rihanna
@rihanna
98.5M followers
NASA
@nasa
92.4M followers
Justin Bieber
@justinbieber
91.7M followers
KATY PERRY
@katyperry
89.5M followers
Taylor Swift
@taylorswift13
83.5M followers
Lady Gaga
@ladygaga
74.9M followers
Virat Kohli
@imvkohli
72.6M followers
Kim Kardashian
@kimkardashian
70.7M followers
YouTube
@youtube
68.8M followers
Neymar Jr
@neymarjr
65.6M followers
Bill Gates
@billgates
64.9M followers
Selena Gomez
@selenagomez
62.6M followers
The Ellen Show
@theellenshow
62.3M followers
CNN
@cnn
61.8M followers
X
@x
60.8M followers